Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eleni Efstathiou

Showing results (101-110 of 150) with videos related to

Pageof 15
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 15

Showing results (101-110 of 150) with videos related to

Sort By:
Pageof 15
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Oncogene|September 29, 2021
Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuelEstefania Labanca, Juan Bizzotto, Pablo Sanchis, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Medicine|March 28, 2017
VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancerJianjun Gao, John F Ward, Curtis A Pettaway, et al.
Lancet (London, England)|April 20, 2010
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 studyHoward I Scher, Tomasz M Beer, Celestia S Higano, et al.
The Lancet. Oncology|February 8, 2022
Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trialMatthew R Smith, Howard I Scher, Shahneen Sandhu, et al.
The Lancet. Oncology|October 3, 2021
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 studyFred Saad, Eleni Efstathiou, Gerhardt Attard, et al.
Clinical Genitourinary Cancer|March 19, 2018
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted AgentsAntoine Angelergues, Eleni Efstathiou, Revekka Gyftaki, et al.
European Urology Oncology|May 6, 2025
Niraparib and Abiraterone Acetate plus Prednisone in Metastatic Castration-resistant Prostate Cancer: Final Overall Survival Analysis for the Phase 3 MAGNITUDE TrialKim N Chi, Elena Castro, Gert Attard, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Pageof 15